Literature DB >> 17556023

Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease.

Rui Yang1, Zhao Cui, Thomas Hellmark, Marten Segelmark, Ming-hui Zhao, Hai-yan Wang.   

Abstract

Anti-GBM disease is a rare autoimmune condition characterized by autoantibodies targeting the alpha3 chain non-collagen 1 domain of type IV collagen (alpha3(IV)NC1). Recently, we isolated IgG reacting with alpha3(IV)NC1 from normal healthy human sera. The current study examined the antigen and epitope specificity of these natural autoantibodies (NAA) using recombinant human alpha1, 3, 5(IV)NC1 and three constructs expressing, previously defined epitope regions designated E(A), E(B) and S2, in the alpha1(IV)NC1 background. The NAA preparations reacted with recombinant human alpha3(IV)NC1 to the same extent as with purified bovine alpha(IV)NC1, but not with recombinant human alpha1 and alpha5(IV)NC1. NAA preparations recognized the three chimeric proteins (E(A), E(B) and S2) yielding similar absorbance values. We conclude that anti-GBM NAA recognize the same major epitopes as anti-GBM antibodies from patients with Goodpasture's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556023     DOI: 10.1016/j.clim.2007.05.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  11 in total

Review 1.  Goodpasture's disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis.

Authors:  Vadim Pedchenko; Roberto Vanacore; Billy Hudson
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-05       Impact factor: 2.894

2.  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'.

Authors:  John Reynolds; Gloria A Preston; Barrak M Pressler; Peter Hewins; Michael Brown; Aleeza Roth; Elizabeth Alderman; Donna Bunch; J Charles Jennette; H Terence Cook; Ronald J Falk; Charles D Pusey
Journal:  J Autoimmun       Date:  2015-04-02       Impact factor: 7.094

3.  Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.

Authors:  Rana Grillberger; Veronica C Casina; Peter L Turecek; X Long Zheng; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

4.  Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease.

Authors:  Stephen W Olson; Charles B Arbogast; Thomas P Baker; David Owshalimpur; David K Oliver; Kevin C Abbott; Christina M Yuan
Journal:  J Am Soc Nephrol       Date:  2011-08-25       Impact factor: 10.121

Review 5.  Advances in human antiglomerular basement membrane disease.

Authors:  Zhao Cui; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

6.  Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay.

Authors:  Alexander Kühnl; Lea Hartwig; Cornelia Dähnrich; Wolfgang Schlumberger
Journal:  Front Med (Lausanne)       Date:  2022-07-04

7.  Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury.

Authors:  Jun-liang Chen; Shui-yi Hu; Xiao-yu Jia; Juan Zhao; Rui Yang; Zhao Cui; Ming-hui Zhao
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

8.  The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif.

Authors:  Shui-Yi Hu; Qiu-Hua Gu; Jia Wang; Miao Wang; Xiao-Yu Jia; Zhao Cui; Ming-Hui Zhao
Journal:  J Cell Mol Med       Date:  2017-03-10       Impact factor: 5.310

9.  Antibody-negative Goodpasture's disease.

Authors:  Mordecai Stolk; Daniel Carl; H Davis Massey
Journal:  NDT Plus       Date:  2010-03-30

Review 10.  Streptococcal Enzymes as Precision Tools Against Pathogenic IgG Autoantibodies in Small Vessel Vasculitis.

Authors:  Mårten Segelmark; Lars Björck
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.